Summary
The provided AI statements are largely unrelated to the FDA-approved indications and use route for Magnesium Sulfate in 5% Dextrose Injection (IV) and include multiple claims about oral supplementation, statin (Lipitor) muscle cramps, dosing regimens, and monitoring that are not supported by the supplied prescribing information excerpts.
Category Scores
Accurate Statements
Lipitor inhibits HMG-CoA reductase.
Not present in the supplied label excerpts for Magnesium Sulfate in 5% Dextrose Injection; cannot be verified against the provided prescribing information.
Unsupported Statements
Magnesium supplements may ease muscle cramps linked to Lipitor (atorvastatin).
The label excerpts for magnesium sulfate injection are for prevention/control of seizures in pre-eclampsia/eclampsia and do not support use for statin-associated muscle cramps or oral magnesium supplementation.
Statins can deplete magnesium levels and disrupt muscle function.
No supporting language in the provided labeling excerpts.
Studies show statins reduce blood magnesium by 10-20% in some patients.
No supporting language in the provided labeling excerpts.
Myalgia (muscle pain or cramps) occurs in up to 10-15% of statin users.
No supporting language in the provided labeling excerpts.
Supplementing 300-600 mg daily of magnesium (as citrate or glycinate) has helped reduce symptoms in small trials and case reports.
The supplied label excerpts do not describe oral magnesium dosing, formulations (citrate/glycinate), or treatment of statin-related symptoms.
A review found 78% improvement in statin-related myopathy with magnesium supplementation.
No supporting language in the provided labeling excerpts.
Inhibiting cholesterol synthesis indirectly reduces CoQ10 and magnesium.
No supporting language in the provided labeling excerpts.
CoQ10 and magnesium are needed for muscle contraction and relaxation.
No supporting language in the provided labeling excerpts.
Lipitor can lead to cramps, weakness, or fatigue.
No supporting language in the provided labeling excerpts (label is for magnesium sulfate injection).
Symptoms often start 1-6 months after statin use.
No supporting language in the provided labeling excerpts.
Risk of muscle cramps increases with higher doses (>40 mg) of Lipitor.
No supporting language in the provided labeling excerpts.
Risk of muscle cramps increases with age over 65.
No supporting language in the provided labeling excerpts.
Risk of muscle cramps increases with low vitamin D.
No supporting language in the provided labeling excerpts.
Risk of muscle cramps increases with hypothyroidism.
No supporting language in the provided labeling excerpts.
A 2018 trial gave 400 mg magnesium oxide to 40 statin users with cramps.
No supporting language in the provided labeling excerpts.
In that 2018 trial, 60% of participants reported relief with 400 mg magnesium oxide versus 20% on placebo.
No supporting language in the provided labeling excerpts.
Low serum magnesium (<1.8 mg/dL) is linked to worse symptoms in observational data.
No supporting language in the provided labeling excerpts.
Correcting low magnesium with supplements or diet often resolves issues.
No supporting language in the provided labeling excerpts.
A 2022 meta-analysis found inconsistent benefits of magnesium and stressed individual testing of magnesium levels first.
No supporting language in the provided labeling excerpts.
The evidence does not include large RCTs confirming magnesium universally alleviates statin-induced muscle cramps.
No supporting language in the provided labeling excerpts.
Magnesium is described as low-risk and commonly recommended by doctors.
No such statements are present in the supplied labeling excerpts; the label includes risk of magnesium intoxication and other serious adverse outcomes with parenteral administration.
An initial magnesium dosage of 200-400 mg elemental magnesium daily is suggested.
The supplied label excerpts provide IV dosing context for pre-eclampsia/eclampsia and do not support oral elemental magnesium daily dosing for statin-associated cramps.
Splitting magnesium doses helps avoid diarrhea.
No supporting language in the provided labeling excerpts.
Glycinate or taurate forms of magnesium are suggested as better suited for cramps with less GI upset.
No supporting language in the provided labeling excerpts.
Avoiding magnesium oxide is suggested due to poor absorption.
No supporting language in the provided labeling excerpts.
Vitamin D supplementation of 1,000-2,000 IU and CoQ10 supplementation of 100-200 mg ubiquinol are suggested for pairing with magnesium.
No supporting language in the provided labeling excerpts.
The response suggests a 'synergy' between magnesium/vitamin D/CoQ10 pairing and statin effects.
No supporting language in the provided labeling excerpts.
Tracking symptoms for 4-6 weeks and using blood tests to guide adjustments is suggested.
The supplied label excerpts discuss serum magnesium monitoring in the setting of renal insufficiency, not a generalized approach for statin-related cramps.
Excess magnesium supplementation (>350 mg supplemental) can cause loose stools.
No supporting language in the provided labeling excerpts.
Excess magnesium supplementation (>350 mg supplemental) can cause low blood pressure.
No supporting language in the provided labeling excerpts.
Kidney issues or drugs like PPIs worsen magnesium deficiency.
No supporting language in the provided labeling excerpts.
Magnesium does not reduce Lipitor efficacy.
No supporting language in the provided labeling excerpts (and no Lipitor-specific interaction information is included).
Magnesium may unmask rare rhabdomyolysis if cramps worsen.
No supporting language in the provided labeling excerpts.
Lipitor should be stopped if severe (CK >10x upper limit).
No supporting language in the provided labeling excerpts.
Testing CK, magnesium, vitamin D, and thyroid before supplementing is suggested.
No supporting language in the provided labeling excerpts.
Cramps with dark urine or swelling signal rhabdomyolysis and require ER care.
No supporting language in the provided labeling excerpts.
If supplements fail, considering dose cut, statin holiday, or alternatives like ezetimibe is suggested.
No supporting language in the provided labeling excerpts.
Contradictions
High
AI Statement
Magnesium supplements may ease muscle cramps linked to Lipitor (atorvastatin).
Label Reference
Indications and Usage in provided label excerpts: magnesium sulfate in 5% dextrose injection is indicated for prevention and control of seizures in pre-eclampsia and eclampsia.
Low
AI Statement
Magnesium sulfate in 5% dextrose injection is intended for intravenous use only / IV infusion.
Label Reference
Dosage and Administration excerpt: magnesium sulfate in 5% dextrose injection is intended for intravenous use only.
Important Omissions
For any discussion of magnesium sulfate (the listed drug), the label requires that it is intended for intravenous use only and provides specific indication (pre-eclampsia/eclampsia seizure prevention/control), which is not addressed in the AI statements.
Importance:
High
Contraindication about not giving IV magnesium to mothers with toxemia of pregnancy during the two hours preceding delivery is not addressed.
Importance:
High
Renal insufficiency warning and need for dose reduction and frequent serum magnesium monitoring are not addressed in the AI statements.
Importance:
High
Fetal harm warning for continuous administration beyond 5 to 7 days during pregnancy is not addressed.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The AI statements promote/center use for statin-associated muscle cramps and provide oral supplement dosing and adjunct regimens that are not supported by the provided prescribing information for magnesium sulfate in 5% dextrose injection (an IV product indicated for pre-eclampsia/eclampsia). The mismatch in drug, route, and intended use raises substantial risk of misleading label-inconsistent use and omits critical label safety requirements (IV-only use, pregnancy fetal harm with prolonged administration, renal insufficiency monitoring, and contraindication).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple label-inconsistent claims about using magnesium (including oral dosing, forms, adjunct supplements, and statin-related outcomes) are not supported by the supplied FDA prescribing information for Magnesium Sulfate in 5% Dextrose Injection, which is for IV use in pre-eclampsia/eclampsia seizure prevention/control.
Suggested Improvement
Restrict statements to the supplied label scope (indication: pre-eclampsia/eclampsia seizure prevention/control; intended route: IV; contraindication and key warnings including renal insufficiency monitoring and fetal harm with prolonged use), and remove unsupported statin/Lipitor and oral supplement dosing claims unless the correct label for those specific claims is provided.